PatientsVisitorsLocations & ServicesAbout the RegionJoin Our TeamPhysicians
Find:  Locations | Services
Pathology and Laboratory Medicine HomeTest and Services CatalogueTransfusion Medicine Product CataloguePolicy and ProcedureJob AidsSpecimen Collection and TransportRequisitionsAntibiogramsGenetic Testing and Molecular GeneticsMicrobiology EssentialsTransfusion EssentialsReference RangesLaboratory SuppliesAcute Care SCM GuidelinesContact InformationPhysician Access to Patient ResultsNew Clinic or Provider Information Changes
Pathology and Laboratory Medicine
Product Catalogue

​Prothrombin Complex Concentrate (PCC)

Transfusion Medicine

​Alternate Product Names
  • PCC
  • ​Beriplex
  • Octaplex
  • ​Urgent reversal of warfarin in patients with an INR of 1.5 or greater with:
    • Major bleeding and/or
    • Need for an unplanned surgical procedure which cannot be delayed a minimum of 6 hours
    • Note: The PCC request should be based on an INR result that is no more than 2 hours from the time it was reported
  • Consideration for management of factor Xa inhibitor (apixaban (Eliquis®), rivaroxaban (Xarelto®), or edoxaban (Lixiana®) associated bleeding. See “Dosing” and “Notes” sections below and/or consult the Transfusion Medicine Physician on-call.
  • Patients with a known heparin allergy or in suspected or proven Heparin Induced Thrombocytopenia (HIT)
  • IgA deficiency with anti-IgA antibodies (applies to Octaplex® only)

  • Not effective for management of:
    • Disseminated Intravascular Coagulopathy (DIC)
    • Liver dysfunction/disease associated coagulopathy
    • Massive transfusion
    • Bleeding associated with heparin based anticoagulants, antiplatelet agents or direct thrombin inhibitors (dabigatran/Pradaxa)
​Resource Information

​Product Monographs:

More Information:

Size/Volume Available
  • 500 units
  • 1000 IU (Octaplex only)


*Note: Rosthern and Humboldt maximum stock availability is 2000 units
Pretransfusion Testing Requirements
  • ​None required
Forms Required


  • Warfarin Reversal for Major Bleeding or Urgent Surgery
​INR 1.5-2.9
INR 3.0-5.0
INR 5.1 or greater
PCC dosage
​1000 units
​2000 units
​3000 units
    •  If the INR is unknown and major bleeding is present in a patient known to be taking warfarin, 2000 units (80 mL) PCC should be administered
    • Maximum dose not to exceed 3000 units
  • Factor Xa Inhibitor Bleeding Management
​Beriplex®/Octaplex® Dose
​Apixaban (Eliquis®)
​25-50 IU/kg x 1
Rivaroxaban (Xarelto®)
​25-50 IU/kg x 1
Edoxaban (Lixiana®)
​25-50 IU/kg x 1
    • Maximum dose not to exceed 3000 IU
    • Contraindicated in patients with a history of Heparin Induced Thrombocytopenia (HIT)
  • Warfarin Reversal for Major Bleeding or Urgent Surgery
  • Direct Oral Anticoagulant (DOAC) Associated Bleeding
  • Adverse reactions including immediate allergic complications are rare. Thrombosis risk is at least 1 in 100, and dependent on individual patient risk factors and PCC dose.
  • ​Administration information can be found in the Nursing Policy and Procedure Manual, the product monograph/package insert and the applicable site Job Aid
  • Must be infused within  3 hours of reconstitution
  • Contains human protein; informed patient consent required for this product
  • A Transfusion Medicine/CBS chart report is NOT required for product infusion


​If you choose to print this information, it is valid only on date of print.

Laboratory Controlled Document LSM-342 v10

Last Modified: Wednesday, October 16, 2019 |
Questions or feedback about this page?